Opinion|Videos|May 2, 2025
45-Year-Old Never-Smoker with Advanced EGFR-Mutant NSCLC and CNS Metastases Treated with the MARIPOSA Regimen
Panelists discuss how a 45-year-old anxious patient who refused chemotherapy was successfully treated with amivantamab plus lazertinib along with prophylactic management strategies for potential adverse effects.
Advertisement
Episodes in this series
Case Presentation 2 – Patient With Treatment Preferences
Main Discussion Topics:
- Management of a 45-year-old preschool teacher with significant anxiety about treatment
- Addressing a patient’s strong preference against chemotherapy
- Implementation of prophylactic strategies for adverse event management
Key Points for Physicians:
- Patient with EGFR exon 21 mutation, numerous brain metastases, and adamant preference against chemotherapy
- Amivantamab + lazertinib selected as a chemotherapy-free option with demonstrated overall survival and central nervous system (CNS) benefits
- Comprehensive prophylactic measures implemented (dexamethasone premedication, skin prophylaxis, anticoagulation)
Notable Insights:
Patient education involved balancing data-driven information about efficacy with counseling about expected toxicities and management strategies.
Clinical Significance:
This case demonstrates how treatment selection can be successfully tailored to align with patient preferences while still providing optimal efficacy for high-risk disease features.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5